Brief: Xintela Gets Notice Of Allowance From USPTO For Quality Assurance Of Chondrocyte-Based Products
29/07/2020 07:52
July 29 (Reuters) - Xintela AB XINT.ST :
* XINTELA RECEIVES NOTICE OF ALLOWANCE FROM USPTO FOR
QUALITY
ASSURANCE OF CHONDROCYTE-BASED PRODUCTS
* ONCE GRANTED, PATENT WILL BE VALID UNTIL 2038.
* NOTICE OF ALLOWANCE MEANS THAT USPTO INTENDS TO GRANT
PATENT
AFTER CERTAIN FORMAL STEPS HAVE BEEN COMPLETED.
Source text for Eikon: ID:nBQNK3Mff
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects